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Point by point response
Reviewer: 1 Comments to the Author Dubos et al report on the knockout of ATP6AP2 in fly and mouse brains. These studies were motivated by two previous reports showing that hypomorphic mutations in ATP6AP2 cause X-linked mental retardation (in one case with parkinsonism and in the other with epilepsy). The mutations affect splicing of exon 4 and also mRNA expression. Yet, one of these mutations has been questioned after its identification in a single male within a cohort of 6,500 sequenced control exomes.
In the current paper, the authors clearly show that ATP6AP2 is required for central nervous systems functions. The combination of fly and mouse assay covers a wide variety of assays regarding memory, locomotion and synaptic functions. On the cellular level, they find that lack of ATP6A2 causes defects in lysosomal and autophagic clearance, consistent with previous reports.
Altogether, the paper is of high quality, contains important findings and should thus be published in HMG.
A couple of points remain, though:
Major points:
1. For the mouse, the authors provide evidence that there is disrupted autophagic clearance in the absence of ATP6AP2. It is likely that the same is true for Drosophila. But it would nonetheless be helpful if autophagy was addressed also in this model, e.g. by co-expressing Atg8-GFP or by using anti-Ref(2)p. On this note, can the synaptic transmission defects as well as bruchpilot accumulation in the photoreceptor neurons and NMJ, respectively, be a result of impaired autophagic/lysosomes defects?
As the referee requested, we now tested and demonstrated a defect in autophagic clearance also in Drosophila. We used immunohistochemistry with the anti-Ref(2)p antibody on Drosophila adult brains.
We observed an increase of Ref (2) Importantly, cell death is unlikely to ('unspecifically') underlie the observed morphological and functional phenotypes. Our previous data showed that the extensive vacuolarization phenotype observed in Drosophila specifically arises from corrupted function of ATP6AP2 or its related molecular machinery: in a large-scale genetic screen we ablated, one by one, 270 orthologues of human intellectual disability genes in the Drosophila eye, using conditions identical to the present study (Reference 22). Although the screen included many genes known to be essential, ectopic vascularization as here reported for ATP6AP2 was exclusively observed for Vha100 -1, a V-ATPase subunit. The same holds true for the electrophysiological profile, together illustrating that the observed defects are quite specific for this pathway and not merely a consequence of cell death. Similarly, the deletion of essential genes leading to cell death would not necessarily induce the morphological, electrophysiological or behavioural alterations observed in our mouse model. For example, the deletion of the carboxypeptidase E (CPE), which induces neuronal degeneration in particular in the CA3 region of the mouse hippocampus (as observed in our mouse model) lead to a profound effect on memory, synaptic physiology and the cytoarchitecture of the hippocampus in these animals. Adult CPE-KO mice displayed memory deficits in the water-maze and object preference (1), which are deficits different from those of our mouse model that did not show any alteration in the watermaze and object preference ( Figure S3 and 4) . Since loss of ATP6AP2 does not induce apoptosis, we did not apply p35, an inhibitor of caspases and apoptosis (2) .
In response to the referee's question, we have included the following comment into the results section (p We evaluated Atp6ap2 Camk2aCre/0 mouse males for susceptibility to seizures either spontaneously using electroencephalography (EEG) recording with cortical electrodes or following injection of a pro-convulsive compound, the Pentylenetetrazol (PTZ). After more than 24h of EEG recording, we did not observe any spontaneous seizures, neither in wt nor in mutant mice. At two different doses of PTZ (30 and 40mg/kg), the percentage of animals showing myoclonic, clonic or tonic seizures was significantly reduced in
Atp6ap2
Camk2aCre/0 mice compared to wt mice (30mg/kg: myoclonic: χ2 = 8.75, p<0.01; clonic: χ2 = 11.43, p<0.001; Figure S5B ; 40mg/kg: myoclonic: χ2 = 6.56, p=0.01; clonic: χ2 = 8.04, p<0.01, tonic: χ2 ≥ 6.23, p=0.0125; Figure S5E ). In addition, the latency of seizure appearance was significantly higher in knockdown was specifically targeted to the mushroom body, a Drosophila adult brain region important for learning, memory and locomoter activity, we could observe some degree of seizures upon banging. These somewhat inconsistent results between mouse and Drosophila make them difficult to interpret. However, it should be noted that in the mouse model, Atp6ap2 is deleted only in Camk2a positive neurons, i.e.
excitatory neurons, but not in inhibitory neurons, whereas in Drosophila models, all neuron types are depleted for ATP6AP2. Indeed, it has been described that epilepsy arise from a sequence of events that converts a normal neuronal network into a hyperexcitable network. Consequently, in the mouse model, where the excitatory neurons degenerate while inhibitory neurons are not affected, seizures would not be induced as the inhibitory network would still be functional.
We have added the methodology used for the experiments in the material and methods section page 32
and the results from the epileptic behavior analysis in the supplemental Figure S4 and in the results section (p 13). The text now reads: "As one of the family with ATP6AP2 mutation presented generalized tonicclonic seizures, we evaluated Atp6ap2 Camk2aCre/0 males for susceptibility to seizures either spontaneously using electroencephalography (EEG) recording with cortical electrodes or following injection of a proconvulsive compound, the Pentylenetetrazol (PTZ). After more than 24h of EEG recording, we did not observed any spontaneous seizures both in wt and Atp6ap2 Camk2aCre/0 mice ( Figure S4A ). We also tested the PTZ, a pro-epileptic drug, at two different doses (30 and 40mg/kg; Figure S4B -G), and we did not find increased susceptibility to seizures. On the contrary the percentage of animals with seizures was reduced and the latency of seizures was increased in the Atp6ap2 Camk2aCre/0 mice compared to wt mice ( Figure S4B -G). Altogether, the data suggest that the deletion Atp6ap2 in glutamatergic neurons mice is unlikely to increase susceptibility to seizures."
We discussed the results from the epileptic behavior analysis in the discussion section (p 22): "One family with ATP6AP2 mutation was reported to have epilepsy, hence we tested the mouse model for epilepsy susceptibility. We did not observed spontaneous epilepsy in Atp6ap2 Camk2aCre/0 mice and mutant mice even had reduced susceptibility to epilepsy induced by PTZ administration. In our mouse model, Atp6ap2 is deleted only in Camk2a positive neurons, i.e. excitatory neurons, but not in inhibitory neurons. Thus, considering the important role of inhibitory neurons in preventing epilepsy, we cannot exclude that the absence of epilepsy could be due to the absence of Atp6ap2 deletion in the inhibitory neurons."
Minor points:
1. There is no clear statement in the discussion on the previously shown ATP6AP2 mutations. It would be important to explain how the knockout/knockdown of ATP6AP2 compares to the effect of the mutations.
In other words, should ATP6AP2 be considered when searching for molecular causes of human ID?
Moreover, the authors do not comment on the role of the renin-angiotensin pathway for the brain pathology. This should be done, given that Ramser et al suggest a causative role in their paper. To my feeling, addressing these two points in the discussion would be very informative for the ATP6AP2 community as well as the HMG readership.
The mutations identified in humans are splicing mutations, thus their effects on ATP6AP2 protein are not directly clear. However, several studies showed that the two mutations identified results in significant overexpression (about 50%) of a 150-bp minor splice isoform which produces a protein with an internal deletion of 32 amino acids, and concomitant reduction of the major full size transcripts (References 2, 5).
Moreover, Contrepas and collaborators suggested that ATP6AP2 protein lacking exon 4 (∆4 ATP6AP2)
would acts as a dominant negative protein through dimerization with wild-type ATP6AP2 (Reference 53).
Since we demonstrated that ATP6AP2 deletion in Drosophila and mouse has drastic consequences on neurons, supporting its involvement as a causative gene for ID and Parkinsonism, we suggest that ATP6AP2
should be considered when screening patients with X-linked intellectual disabilities with epilepsy and/or Parkinsonism with spasticity (References 2, 3, 5).
We modified the manuscript in the discussion section (p 24) as follows: "We demonstrated that ATP6AP2 Wnt and/or MAP kinases ERK1/2 signalling, will be extremely interesting."
2.
Having said that, the paper appears quite long, and I would suggest shortening some parts of the result and discussion section.
We did some efforts to shorten the results and discussion parts, and we tried to be concise in the new sections that we added.
Reviewer We suggest that the Camk2a-positive Atp6ap2-negative post-mitotic glutamatergic neurons would progressively die. By immunohistochemistry with anti-Camk2a antibody we observed that glutamatergic neurons were still present on the brain sections (Figure 2) . However a decreased in the density of Camk2a positive cells was observed (Figure 2 D, G) . The electron microscopy images confirmed this result showing neuronal degeneration in the cortex and in the hippocampus (Figure 7 A-D) . Interestingly, the two brain regions corresponded with the regions presenting the highest Atp6ap2 deletion level. To conclude, we suggest that Atp6ap2 deletion affected post-mitotic neuron viability, and lead to neuronal degeneration. We and others have already shown that the observed phenotypes are not shared by other essential genes but can indeed arise from ablation of genes also involved in the ATP6AP2 pathway. We refer to our response to comment 2 of referee 1 for details. In fact, core subunits of the ATP6AP2-interacting V-ATPase have been already described to be important for mediated vesicle fusion in several tissues and organism.
Consequently, defects in several V-ATPase subunits lead to vacuolarization defects e.g. in yeast (3), and to defects in synaptic vesicle exocytosis e.g. in Drosophila (4). It is thus very conceivable that corruption of specific cellular and molecular functions lead to the described mouse and Drosophila phenotypes.
(5) It may be also helpful to focus on features shared by "weak" and "strong" knockdowns (e.g., common
for both RNAi1 and RNAi2 models in Drosophila). This would better represent a "dose-dependent" effect of ATP6AP2 depletion.
Unfortunately, the concept of the referee to focus on shared phenotypes between both RNAi lines with different knockdown levels to describe dose-dependent phenotypes is not clear to us. As described, most 12 abnormal features (bouton morphology, NMJ size, ectopic satellites) are common to both genotypes. The observed differences in phenotype strength as well as a phenotypes exclusively present in the RNAi line 1 (bruchpilot trafficking defects in axons) are in line with RNAi 1 producing the stronger knockdown. This was experimentally verified by qPCR. Axonal defects might thus require a stronger knockdown to manifest.
Due to the speculative character of this suggestion and the already very long text, we prefer not to discuss this point and hope for the referee's understanding.
(6) In the introduction (manuscript page 4, lines 9-13), the authors state that: "implication of ATP6AP2 in intellectual disabilities has been questioned after an ATP6AP2 mutation was identified in a single male individual within a cohort of 6,500 sequenced control exomes". They refer to a paper that reported a neurologically normal adult male with a loss-of-function ATP6AP2 mutation. These are results of a largescale exome sequencing study that used an "early generation" exome technology. Obviously, this variant was not validated (e.g., by Sanger sequencing). Therefore, this "finding" remains dubious. Later on the same page, line 47, they do mention "studies regarding ATP6AP2 in mouse, zebrafish, frog and Drosophila have shown that its full deletion is lethal". How would this human male lacking ATP6AP2 have survived?
We agreed with the referee, the ATP6AP2 mutation identified in a healthy individual within a cohort of 6,500 sequenced control exomes remain dubious since the mentioned mutation have never been confirmed nor studied how it may affect the corresponding protein. Indeed, the mutation identified is also a splicing mutation affecting the last exon of the gene (and not a loss-of-function mutation), thus the consequences of the mutation could be more or less severe (and would probably not lead to the absence of ATP6AP2 protein).
We have changed the discussion (p 24-25) as follows: "We demonstrated that ATP6AP2 depletion in Drosophila and mouse induced behavioural, neuronal and synaptic phenotypes that lead to cognitive impairment and neurodegeneration, which greatly recapitulates the phenotypes associated with ATP6AP2 mutations in human. The two ATP6AP2 mutations identified in humans so far are splicing mutations, both leading to the skipping of the exon 4 of the gene (2, 5) . This results in significant overexpression (about 50%) of a 150-bp minor splice isoform which produces a protein with an internal deletion of 32 amino acids, and concomitant reduction of the major full size transcripts (2, 5). Contrepas and collaborators suggested that ATP6AP2 protein lacking exon 4 (∆4 ATP6AP2) would acts as a negative dominant through dimerization with ATP6AP2 wild-type proteins (51). In XPDS patients, a reduction of the total amount of ATP6AP2 proteins was observed in the brain (5). In contradiction another ATP6AP2 mutation was identified in a male within a cohort of 6,500 sequenced control exomes (3). This mutation is also a splicing mutation affecting the last exon of the gene, however it has never been validated and the consequences of the mutation remain unclear. Since we demonstrated that ATP6AP2 deletion in Drosophila and mouse has drastic consequences on neurons, supporting its involvement as a causative gene for ID and Parkinsonism, we suggest that ATP6AP2 should be considered when screening patients with X-linked intellectual disabilities with epilepsy and/or Parkinsonism with spasticity (2, 3, 5). Indeed, another member of the V-ATPase complex, ATP6V0A2, has also already been implicated in ID (23)."
(7) With respect to the co-localization experiments on manuscript page 13, the description has poor correspondence with figure S4 ; it needs puncta quantification for clarity.
We did not do an Atp6ap2 colocalization quantification as it has already been studied and published by We have modified the results section (p 8) as follows: "In the cortex and the hippocampus, we did not detect Atp6ap2 expression in astrocytes (GFAP marker, data not shown), however, considering the limited sensitivity of immunohistochemistry, we cannot exclude that Atp6ap2 is expressed at low level."
Minor comments:
Manuscript page 4, line 23, delete "first described." ATP6AP2 was initially isolated as a component of V-
ATPase by Ludwig et al, 1998
The referee is correct. We have deleted "first" and the sentence now reads page 4: "ATP6AP2 was described as a receptor for renin and prorenin ((P)RR)."
Manuscript page 12, line 28, the sentence would be easier to read if rephrased, "There is a clear absence of Atp6ap2 labelling in the GFP-expressing area."
We agreed and have rephrased the sentence (now page 12): "As shown in Figure 5B , there is a clear absence of Atp6ap2 labelling in the GFP-expressing area."
Manuscript page 15, line 1 describes panel 6G, not 6H.
The referee is correct, we have corrected this mistake. The sentence (now page 15) now reads: "While inspecting NMJ morphology in pan-neuronally induced ATP6AP2RNAi1 animals, which are characterized by a decreased amount of BRP-positive active zones, we found that BRP strongly accumulated in motor axons ( Figure 6G )."
Manuscript page 16, line 4. The sentence beginning "Taken together, our results suggest that … " is better placed in the Discussion section.
As the referee suggested, we have deleted the sentence "Taken together, our results suggest that …" and added it in the discussion. The sentence is now in discussion section (p 21) and reads: "We suggest that this deregulated autophagy induces the axonal and neuronal degeneration observed in the cortex and hippocampus of Atp6ap2 Camk2aCre/0 mice. Indeed, neurons, particularly axons, are well known to be highly sensible to autophagy dysregulation, resulting in degeneration (35)."
Manuscript page 22, line 33. The one sentence paragraph beginning "Here we demonstrated that ATP6AP2
depletion…" should be deleted as it repeats the points of the first sentence of the Discussion on manuscript page 19, line 5. This sentence would be better phrased as "Data are consistent with…" and should be merged with the following paragraph.
The referee is correct. We have changed both sentences in the revised manuscript. The discussion part (now p 19) now starts with: "Here we investigated the role of ATP6AP2 in the nervous system of two model models, mouse and Drosophila. The identified phenotypes are largely consistent in both organisms and suggest an essential role of ATP6AP2 for nervous system development, basal synaptic transmission and cognitive functions." And the last paragraph of the discussion (now p 24) now starts with: "We demonstrated that ATP6AP2 depletion in Drosophila and mouse induced behavioural, neuronal and synaptic phenotypes that lead to cognitive impairment and neurodegeneration, which greatly recapitulates the phenotypes associated with ATP6AP2 mutations in human."
